Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc
Bullboard Posts
User Avatar Image
(1)
•••
Comment by indoubtgetouton Nov 10, 2020 3:49pm
91 Views
Post# 31872007

RE:RE:RE:RE:RE:RE:RE:RE:Be greedy when others are fearful

RE:RE:RE:RE:RE:RE:RE:RE:Be greedy when others are fearful Hey Mugsy, you should buy a pot stock as you have been smoking so much that you should profit from all that money spent!   Gee whiz, your pumping is getting annoying so I am just going to keep responding accordinlgy.   Paper losses are still losses - those that really understand investing understand that their portfolios are "marked to market" each trading minute.   GUD has been a total disappointment - in fact the WALL OF SELLERS is getting so great that sholud GUD have anything remotely positive happen within JGOODY's camp, can't see GUD ever getting over $7.50...so ya, keep pumping  as I doubt you even hold any shares...you are probably hired by JGOODY to write your daily DUMP!   JGOODY and his TEAM are a bunch of LOSERS!!   Stock price is reflection of that....
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities